跳转至内容
Merck
CN

HNDG1MAG-36K

MILLIPLEX® 人神经退行性疾病磁珠板1-神经科学多重分析

Configurable Human Neurodegenerative Disease 6-Plex Panel 1

登录 查看组织和合同定价。

关于此项目

UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000


产品名称

MILLIPLEX® 人神经退行性疾病磁珠板1-神经科学多重分析,

description

Configurable Human Neurodegenerative Disease 6-Plex Panel 1

Quality Level

species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

assay range

accuracy: 105%
(Complement Factor H), accuracy: 110%
(Apo E), accuracy: 75%
(Complement C3), intra-assay cv: <10, standard curve range: 0.01-40 ng/mL
(Apo CIII), standard curve range: 0.05-200 ng/mL
(Apo E, Complement C3), standard curve range: 0.3-1,000 ng/mL
(Complement Factor H), standard curve range: 0.5-2,000 ng/mL
(α-2-Macroglobulin), standard curve range: 0.7-3,000 ng/mL
(Apo A1)

technique(s)

multiplexing: suitable

input

cerebrospinal fluid (CSF)
plasma
cell culture supernatant(s)
serum

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

General description

Disruptions in lipid transport and innate immunity are central to the pathology of neurodegenerative diseases. α-2-Macroglobulin, a broad-spectrum protease inhibitor, is closely linked to neuronal injury and Alzheimer′s progression. Apolipoproteins AI, CIII, and E orchestrate cholesterol balance and lipid trafficking—processes that falter early in cognitive decline. Meanwhile, complement proteins like C3 and Factor H influence synaptic pruning and amyloid clearance, with elevated levels often marking the onset of mild cognitive impairment.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 6 analytes in human serum, plasma, and cerebrospinal fluid (CSF).

Analytes included: α-2-Macroglobulin, Apo AI, Apo CIII, Apo E, Complement C3, Complement Factor H.

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

  • Comprehensive Metabolic-Immune Profiling: Simultaneously quantify lipid metabolism markers, complement factors, and innate immune proteins, providing complete insight into the metabolic and inflammatory pathways driving neurodegeneration.
  • Early-Stage Detection Power: Leverage biomarkers that show significant elevation in mild cognitive impairment.
  • Batch-to-Batch Excellence: Trust in stringent manufacturing standards with verified lot-to-lot consistency ensuring reproducible results.
  • All-in-One Research Solution: Receive complete experimental confidence with our comprehensive kit format containing all necessary reagents, eliminating procurement delays and ensuring seamless workflow execution.
  • Dedicated Research Support: Partner with our specialized neuroscience application scientists and technical experts who can support your multiplex assay needs.

Legal Information

Luminex is a registered trademark of Luminex Corporation
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.


Still not finding the right product?


signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

存储类别

10 - Combustible liquids

wgk

WGK 3

法规信息

新产品

此项目有



分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


相关内容

通过适合的免疫检测产品,探索神经免疫和神经炎症细胞因子及神经退行性疾病生物标志物。

Learn how multiplex detection of Alzheimer’s disease biomarkers, using the MILLIPLEX® Human Amyloid Beta and Tau Magnetic Bead Panel, allows for a different perspective on neurodegenerative disease research.

Neuroscience multiplex assays, such as MILLIPLEX® multiplex assays, enable simultaneous measurement of neuroscience-related biomarkers to gain a better picture of neurodegenerative diseases, neurological disorders, and neuropeptide/neurohormone signaling.

查看所有相关内容

William T Hu et al.
Acta neuropathologica communications, 4, 14-14 (2016-02-19)
CSF levels of established Alzheimer's disease (AD) biomarkers remain stable despite disease progression, and non-amyloid non-tau biomarkers have the potential of informing disease stage and progression. We previously identified complement 3 (C3) to be decreased in AD dementia, but this
Cerebrospinal fluid complement activation in patients with pneumococcal and meningococcal meningitis.
Mook-Kanamori, BB; Brouwer, MC; Geldhoff, M; Ende, Av; van de Beek, D
The Journal of Infection null
Abdul Hye et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 10(6), 799-807 (2014-07-12)
The study aimed to validate previously discovered plasma biomarkers associated with AD, using a design based on imaging measures as surrogate for disease severity and assess their prognostic value in predicting conversion to dementia. Three multicenter cohorts of cognitively healthy